The purpose of the REPRISE study is to evaluate the safety and effectiveness of an investigational medication called tolvaptan in patients with late stage 2 to early stage 4 chronic kidney disease caused by autosomal dominant polycystic kidney disease (ADPKD). The kidney function of participants will be checked through frequent blood tests.
The kidneys of people who have ADPKD do not respond correctly to a hormone called vasopressin. It is believed that vasopressin plays a role in the development and growth of kidney cysts. It is hoped that tolvaptan will interfere with or block the effect that vasopressin has on the kidneys to reduce cyst growth and delay kidney failure.
Who can participate?
You may be able to join the study if you are:
Between the ages of 18 to 55 years old; patients aged 56 to 65 may be able to participate in some circumstances
Diagnosed with ADPKD
There are other criteria that you must meet to participate. The study staff can discuss these criteria with you in greater detail.
What will happen during the study?
If you are eligible and agree to participate in the study, you will be required to:
Visit the study clinic up to 25 times. Depending on your circumstances, you may be offered an opportunity to have certain study visits performed at your home or another location more convenient than the study clinic, if this option is available in your region
Take the investigational medication twice a day as directed by the study doctor
Have blood and urine tests
Drink enough fluids (a minimum of 8 to 12 glasses during the day)
For more information: visit www.reprisestudy.com
Enrollment is now closed.